AAO

Kristen Brotherson, vice president, US surgical marketing for Alcon, discusses some of the recent advances in cataract surgery-related technologies, including a new advanced lens for patients with presbyopia (AcrySof IQ Vivity IOL).

Cynthia Matossian, MD, FACS, ABES presents the highlights of a poster on outcomes with dexamethasone intraocular suspension 9% and concomitant postoperative anti-inflammatory medications.

Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.

During AAO 2020, Kathleeen B. Digre, MD, details how a headache in conjunction with visual loss is a scenario that requires an in-depth examination, including evaluation of the visual fields, pupils, and fundus to gather clues to the diagnosis.

Tamer Mahmoud, MD, PhD, discusses autologous retinal transplant (ART) for macular holes, a procedure he developed, which is providing anatomic hole closure in the vast majority of cases as well as increases in visual acuity.

In a presentation at the American Academy of Ophthalmology’s virtual 2020 annual meeting, Amy K. Hutchinson, MD, explained that while Myopia has been occurring at epidemic rates worldwide, research has found that the use of orthokeratology and multifocal contact lenses can provide clinically meaningful reductions in myopia progression.

Prof. Giovanni Staurenghi, chairman of the University Eye Clinic, Department of Biomedical and Clinical Sciences at the University of Milan’s Luigi Sacco Hospital, Italy, discusses his presentation from this year's AAO, including findings from the HARBOR study of macular atrophy in AMD patients treated with ranibizumab.

Ram Liebenthal, U.S. general manager for Heidelberg Engineering, discusses how the company continues to invest in the Spectralis platform in terms of hardware and software improvements.

Josh Anderson, head of U.S. retina sales and marketing for Alcon, outlines what attendees will learn including product updates, new technologies, and practice management materials for ophthalmologists and their patients during the COVID-19 pandemic.

Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.

Ted Leng, MD, MS, Byers Eye Institute at Stanford, and medical advisor for Verana Health, talks about data insights for retinal surgeons. Steven D. Schwartz, MD, Stein Eye Institute, UCLA, highlights his AAO presentation, “New Insight into Real-World U.S. Injection Data."

Gene therapy for X-linked retinitis pigmentosa is achieving significant visual gains at 1 year mark.

During Day 1 of AAO 2020, Carl Awh, MD, discusses the Micro-Vacuum Pick, a device for peeling internal limiting membranes that's providing vitreoretinal surgeons an alternative to forceps during surgeries.

At AAO 2020, Fernando Arevalo, MD, PhD, details the use of anti-VEGF therapy for the treatment of retinal arteriolar macroaneurysms that are near the fovea.

Prof. Marie-José Tassignon, past chief and chair, Department of Ophthalmology, Antwerp University and University Hospital Antwerp, Belgium, expands on her AAO presentation by providing an overview of her novel technique in performing a risk-free posterior capsulorhexis.

Chris Brittain, MBBS, BSc, MBA, MRCOphth, vice president and global head of ophthalmology product development for Genentech, provides an overview of the company’s podium presentations from the PDS with ranibizumab to faricimab.

Anne L. Coleman, MD, president of the American Academy of Ophthalmology, offers a preview of its virtual 2020 annual meeting.

American Academy of Ophthalmology (AAO) President Anne L. Coleman, MD, PhD, offers a preview of what attendees can look forward to from the academy's 2020 virtual annual meeting — kicking off Nov. 13-15.

Patrik De Haes, MD, CEO of Oxurion NV, shares the latest updates in clinical studies at the OIS@AAO meeting in Chicago, Oct. 2018.

Clinical trial data focusing on treatment for age-related macular degeneration (AMD) have been a highlight at many recent ophthalmology meetings. Here are a few of the latest clinical trials that physicians need to be aware.

Since February is designated Age-Related Macular Degeneration Awareness month. For healthcare providers, there are numerous resources available to help promote awareness to patients and to encourage patients to continue (or start) annual visual exams.